Structure Therapeutics Stock Is Up 47%, but One Fund Just Fully Exited a $2.6 Million Position

On May 8, 2026, ACT Capital Management reported selling all 38,500 shares of Structure Therapeutics (NASDAQ:GPCR), an estimated $2.63 million trade based on quarterly average pricing.According to its SEC filing dated May 8, 2026, ACT Capital Management fully exited its position in Structure Therapeutics during the first quarter. The fund sold all 38,500 shares, with the estimated transaction value at $2.63 million based on the average closing price for the quarter. The net position change, which includes both trading and price effects, was a $2.68 million decrease. The fund now reports no shares in the company.Structure Therapeutics Inc. is a clinical-stage biotechnology company specializing in the development of novel oral small-molecule therapeutics for chronic diseases with significant unmet needs. The company leverages expertise in G-protein-coupled receptor (GPCR) drug targets to advance candidates in metabolic, pulmonary, and cardiovascular indications. Its strategy centers on innovation in oral drug design, aiming to provide differentiated therapies in competitive, high-growth markets.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool